OncLive TV

Guenther Koehne, MD, PhD, discusses the real-life study of CAR T-cell agents axicabtagene ciloleucel vs tisagenlecleucel in patients with relapsed or refractory diffuse large B-cell lymphoma.

Benjamin Heyman, MD, discusses the evolution of BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Tomer Mark, MD, discusses making sequencing decisions amid the array of available treatment options in multiple myeloma.

Daniel Sherbenou, MD, PhD, discusses selecting between available treatment options for patients with late relapsed multiple myeloma.

Bradley J. Monk, MD, FACS, discusses the emergence and utility of NaPi2b as a target in ovarian cancer.

Jan A. Burger, MD, PhD, discusses choosing frontline therapy in chronic lymphocytic leukemia.

Adam M. Brufsky, MD, PhD, FACP, discusses efficacy data with enobosarm in metastatic estrogen receptor–positive, androgen receptor–positive, HER2-negative breast cancer.

Sara M. Tolaney, MD, MPH, chief, discusses the importance of evaluating enobosarm in metastatic estrogen receptor–positive, HER2-negative breast cancer.

Marshall Posner, MD, shares his clinical experience with the use of tipifarnib in patients with head and neck cancer whose tumors harbor HRAS mutations.

Lori J. Wirth, MD, discusses the utility of tipifarnib in patients with head and neck cancer whose tumors harbor HRAS mutations.

Alessandra Larocca, MD, PhD, discusses the various factors to consider when selecting treatment for difficult-to-treat patients with relapsed/refractory multiple myeloma.

Bradley J. Monk, MD, FACS, FACOG, discusses existing unmet needs in the treatment of patients with recurrent ovarian cancer.

Ashish Manne, MBBS, discusses the need to develop novel therapies for patients with hepatocellular carcinoma without preserved liver function.

Marina Kremyanskaya, MD, PhD, discusses the next steps of the phase 1/2 MANIFEST trial in myelofibrosis.

Shikha Jain, MD, FACP, discusses the push toward personalized treatment approaches in colorectal cancer with liver metastases.

Tycel Jovelle Phillips, MD, discusses navigating treatment selection with BTK inhibitors in mantle cell lymphoma.

Paolo Ghia, MD, PhD, discusses the key takeaways of the phase 2 CAPTIVATE study in chronic lymphocytic leukemia.

Ravin Ratan, MD, MEd, discusses the steps that should be taken to diagnose desmoid tumors.

Matthew Galsky, MD, discusses the evolution of standard of care treatment options in urothelial carcinoma.

Daniel Sherbenou, MD, PhD, discusses future directions with maintenance therapy in patients with relapsed/refractory multiple myeloma who received CAR T-cell therapy.

Mario Spaggiari, MD, discusses the potential utility of liver transplantation as a treatment option for patients with colorectal cancer liver metastases.

Melissa L. Johnson, MD, discusses new drug approvals for EGFR exon 20 insertion mutation–positive non–small cell lung cancer.

Rahul Banerjee, MD, discusses the rationale to create a supportive mobile health companion app for CAR T-cell therapy recipients and their caregivers ​to use throughout the therapeutic process.

Kathryn A. Gold, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses current unmet needs in squamous cell carcinoma of the lung.

Tanios S. Bekaii-Saab, MD, FACP, discusses the addition of bevacizumab to trifluridine/tipiracil in patients with metastatic colorectal cancer

Kathryn Gold, MD, discusses best practices with the use of sotorasib in patients with KRAS G12C–mutated non–small cell lung cancer.

Peter Riedell, MD, discusses the patient population and design of a dynamic landmark analysis conducted in patients with mantle cell lymphoma.

Mothaffar Fahed Rimawi, MD, discusses the clinical implications of the phase 3 FeDeriCa trial in early-stage, HER2-positive breast cancer.

Mazyar Shadman, MD, MPH, discusses the safety profile of MB-106, a third-generation, CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Amado J. Zurita-Saavedra, MD, discusses emerging frontline therapies in metastatic hormone-sensitive prostate cancer.